The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals after-the-fact rebates for two drugs in the 340B drug discount program, instead of offering upfront discounts.
The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals after-the-fact rebates for two drugs in the 340B drug discount program, instead of offering upfront discounts.